U

University of Texas Health Science Center at Houston | McGovern Medical School - ACTAT - Research Department

Research site
(Unclaimed)
Location
6410 Fannin Suite 720, Houston, Texas, United States of America
Site insights

Top conditions

Birth Weight (20 trials)

COVID-19 (14 trials)

Premature Birth (12 trials)

Wounds and Injuries (10 trials)

Ischemia (8 trials)

Top treatments

GED-0301
KRN23
Fluvoxamine
Hydrocortisone
Argatroban
Montelukast
Cisplatin
Cocaine
Glutamine
Ibrexafungerp

Parent organization

This site is a part of University of Texas Health Science Center at Houston

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

25 of 204
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-1)

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Enrolling
Refractory Chronic Cough
Drug: BLU-5937
Drug: Placebo

Stroke is one of the leading causes death and major functional disability worldwide. Treatment options for acute stroke are limited with many patient...

Active, not recruiting
Acute Ischemic Stroke
Drug: Placebo
Drug: Elezanumab
Locations recently updated

The primary objectives of the study are to evaluate the efficacy of BIIB059 (litifilimab) compared with placebo in reducing skin disease activity mea...

Enrolling
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Drug: BIIB059 (litifilimab)
Drug: Placebo

This Phase 3 study will assess the safety and efficacy of inclacumab, a P-selectin inhibitor, in reducing the frequency of vaso-occlusive crises (VOC...

Active, not recruiting
Vaso-occlusive Crisis
Vaso-occlusive Pain Episode in Sickle Cell Disease
Drug: Placebo
Drug: Inclacumab
Locations recently updated

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Dupilumab

Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the...

Enrolling
High-risk Transient Ischemic Attack
Acute Non-cardioembolic Ischemic Stroke
Drug: Placebo
Drug: Asundexian (BAY2433334)

The purpose of this study is to find a more effective treatment for allergic fungal rhinosinusitis (AFRS). Most people suffering from nasal polyps ha...

Enrolling
Allergic Fungal Rhinosinusitis
Drug: Placebo
Drug: Dupilumab 300 MG/2 ML Subcutaneous Solution

The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post Approval Set...

Enrolling
Stroke
Patent Foramen Ovale
Device: AMPLATZER™ PFO Occluder

This is a randomized, double-blinded, placebo-controlled, two-arm study to evaluate the safety and efficacy of BIO 300 Oral Suspension (BIO 300) as a...

Enrolling
COVID-19
Pulmonary Fibrosis
Drug: Placebo
Drug: BIO 300 Oral Suspension

The AMPLATZER Muscular VSD Occluder was approved by the US Food and Drug Administration (FDA) in September, 2007. This study is designed to further e...

Active, not recruiting
Ventricular Septal Defects
Device: Muscular VSD Occluder device implantation (AMPLATZER Muscular VSD Occluder)

The objective of this study is to investigate whether percutaneous PFO closure with the Occlutech Flex II PFO Occluder is non-inferior to the AMPLATZ...

Enrolling
Stroke
Patent Foramen Ovale
Device: Investigational PFO Closure Device
Device: Standard of Care PFO Closure Device

This study will evaluate the safety and effectiveness of the Edwards SAPIEN 3/SAPIEN 3 Ultra Transcatheter Heart Valve (THV) compared with clinical s...

Active, not recruiting
Aortic Stenosis, Severe
Heart Diseases
Device: Edwards SAPIEN 3 / SAPIEN 3 Ultra THV

To demonstrate the safety and effectiveness of the Reducer system for treatment of patients with refractory angina pectoris treated with maximally to...

Enrolling
Refractory Angina
Device: Arm 1: treatment with Neovasc Reducer
Device: Arm 3 (unblinded, non-randomized): Single arm registry
Locations recently updated

The purpose of this trial is to generate clinical evidence related to key performance outcomes of Endurant II/IIs Stent Graft Systems verses Gore Exc...

Enrolling
Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)
Abdominal Aortic Aneurysm
Device: Gore Excluder or Gore/ Excluder Conformable AAA Endoprosthesis
Device: Medtronic Endurant II or Endurant IIs Stent Graft System

This trial will evaluate Orbital Atherectomy compared to conventional balloon angioplasty technique for the treatment of severely calcified lesions p...

Active, not recruiting
Ischemic Heart Disease
Coronary Artery Disease
Device: Orbital Atherectomy
Device: Balloon

The goal of Parts A and B of this Phase 1, first-in-human, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of singl...

Enrolling
Phenylketonuria
Drug: Placebo Tablet
Drug: Placebo Suspension

The purpose of this clinical study is to assess the safety and effectiveness of the Atrial Flow Regulator in the treatment of subjects, 18 years of a...

Active, not recruiting
Heart Failure With Preserved Ejection Fraction (HFpEF)
Heart Failure With Reduced Ejection Fraction (HFrEF)
Device: Sham Comparator
Device: Atrial Flow Regulator

This single-blind randomized control study will follow 142 subjects across 7 sites randomized on a 1:1 ratio to compare treatment efficacy and safety...

Enrolling
Hiatal Hernia
GERD
Procedure: LAPAROSCOPIC PARAESOPHAGEAL HIATAL HERNIA REPAIR COMBINED WITH TRANSORAL INCISIONLESS FUNDOPLICATION

A prospective, single-arm, multi-center post-market surveillance study of the BD® WavelinQ™ EndoAVF System for the Creation of Arteriovenous (AV) Fis...

Enrolling
Kidney Disease, End-Stage
Arteriovenous Fistula
Device: EndoAVF Creation

Various patient groups with the On-X Valve can be maintained safely on lower doses of blood thinner(Coumadin®) or on antiplatelet drugs (aspirin/Plav...

Active, not recruiting
Heart Valve Disease
Device: On-X Valve with Standard warfarin Therapy
Device: On-X valve using reduced anticoagulation

Trial sponsors

N

NICHD Neonatal Research Network (37 trials)

The University of Texas System (UT) logo

The University of Texas System (UT) (30 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems